Carter Franke, the chair of the board of directors at Sallie Mae, expressed confidence in the new appointments, stating that ...

In the primary analysis for Harmoni-2, ivonescimab monotherapy demonstrated a statistically significant improvement in the trial’s primary endpoint, progression-free survival (PFS), achieving a hazard ...